OSR Holdings Inc. Common Stock (OSRH)

FairStock Score: 54/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses, honest financials, and a margin of safety. OSR Health at $0.19 a share, a $6.7M market value at the close on 2026-10-13, is not that today. In fiscal 2025, the company filed revenue of $2.9M and a net loss of $27.1M, with diluted EPS of -$0.80. That is a sharp break from fiscal 2024, when it filed revenue of $3.5M and a net loss of $2.4M, and from fiscal 2023, when it filed net income of $403,780. The Lynch category is TURNAROUND — loss in the latest year after earlier profits — and the recent filed quarters support the caution: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $315,669 and net loss was $1.0M; in fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $484,057.41 and net loss was $3.5M; in fiscal Q3 2025, the quarter ended 2025-09-30, revenue was $627,747 and net loss was $3.2M. Free cash flow is -$4.5M, a -67.5% FCF yield on the market cap. FairStock's Piotroski F-Score is 2/9 and Altman Z-Score is -0.47, both signs of financial weakness. The low debt-to-equity of 0.04 and FairStock's P/B of 0.06 offer some asset-value appeal, but a 22-person biotech with early-stage assets can burn book value quickly. The pipeline, including VXM01 after phase 2 for glioblastoma, is optionality, not a proven moat. I see a speculative turnaround, not a margin-of-safety bargain.

In plain English: OSR Health is a small healthcare company that develops experimental immunotherapy treatments. Its sales are tiny and shrinking, and it is losing money, so the business looks weak. The stock price is very low compared with its stated accounting value, but because it is burning cash, cheapness is not clearly a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer